Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary dural lymphomas: a review.

Fabio M Iwamoto1, Lauren E Abrey

  • 1Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, USA.

Neurosurgical Focus
|December 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eosinophil counts as a prognostic marker in glioblastoma: a retrospective cohort study.

BMC cancer·2026
Same author

Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study.

Blood·2026
Same author

Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Post-Chemoradiation Lymphopenia and Baseline Eosinophil Counts as Prognostic Markers in Glioblastoma.

Research square·2025
Same author

Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma.

Neuro-oncology·2025
Same journal

Letter to the Editor. Enhancing comparability in idiopathic intracranial hypertension research through standardized outcome measures.

Neurosurgical focus·2026
Same journal

Introduction. Contemporary spinal arthroplasty.

Neurosurgical focus·2026
Same journal

Cervical disc arthroplasty as a safe and effective procedure for obese patients.

Neurosurgical focus·2026
Same journal

Comparing the operational metrics and functional outcomes of lumbar arthroplasty implants: a systematic review.

Neurosurgical focus·2026
Same journal

Long-term reoperation risk after cervical disc arthroplasty versus fusion: a level-matched meta-analysis of FDA investigational device exemption studies and international randomized trials.

Neurosurgical focus·2026
Same journal

Total disc replacement versus lumbar interbody fusion for degenerative disc disease: a meta-analysis of randomized controlled trials.

Neurosurgical focus·2026
See all related articles

Primary dural lymphoma (PDL) is a rare, low-grade marginal zone lymphoma distinct from other CNS lymphomas. While responsive to local therapy, PDL carries a high risk of systemic relapse due to its location outside the blood-brain barrier.

Area of Science:

  • Neuro-oncology
  • Hematology
  • Pathology

Background:

  • Primary dural lymphoma (PDL) is a rare central nervous system (CNS) malignancy originating from the dura mater.
  • PDL is biologically distinct from other primary CNS lymphomas (PCNSLs), typically presenting as a low-grade marginal zone lymphoma (MZL).
  • In contrast, other PCNSLs are usually high-grade, diffuse, large B-cell lymphomas.

Purpose of the Study:

  • To characterize the unique biological and clinical features of primary dural lymphoma.
  • To differentiate PDL from other CNS lymphomas and meningioma.
  • To evaluate treatment response and prognosis for PDL.

Main Methods:

  • Review of clinical presentations and imaging findings of PDL.
  • Histopathological analysis to confirm MZL subtype.

Related Experiment Videos

  • Assessment of treatment outcomes including response rates and relapse patterns.

    • Main Results:

    • PDL typically presents as single or multiple extra-axial masses with diffuse contrast enhancement, mimicking meningioma.
    • Low-grade MZLs demonstrate excellent response to local therapies like surgery and radiation.
    • High rates of complete response and local disease control are observed.

    Conclusions:

    • Primary dural lymphoma is a distinct entity with a favorable local response to therapy.
    • The location of PDL outside the blood-brain barrier contributes to a significant risk of systemic relapse.
    • Further research is needed to address the systemic recurrence risk in PDL patients.